Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma

Sponsor

H. Lee Moffitt Cancer Center and Research Institute (Other)

Overall Status

Active, not recruiting

CT.gov ID

NCT03071406

Collaborator

Bristol-Myers Squibb (Industry)

Enrollment

Locations

Arms

75.6

Anticipated Duration (Months)

Patients Per Site

0.3

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this study is to test the effectiveness, safety, and tolerability of the drugs nivolumab plus ipilimumab with or without the addition of stereotactic body radiation therapy (SBRT). Nivolumab is an antibody (a type of human protein) that is being tested to see if it will stimulate the body's immune system to work against tumor cells. This study will test an investigational use of nivolumab.

Condition or Disease	Intervention/Treatment	Phase
Merkel Cell Carcinoma Skin Cancer	Drug: Nivolumab Drug: Ipilimumab Radiation: Stereotactic Body Radiation Therapy (SBRT)	Phase 2

Study Design

Study Type:

Interventional

Actual Enrollment :

50 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Intervention Model Description:

Participants are randomly assigned in a 1:1 ratio to Arm A (nivolumab + ipilimumab), or Arm B (nivolumab + ipilimumab + SBRT).Participants are randomly assigned in a 1:1 ratio to Arm A (nivolumab + ipilimumab), or Arm B (nivolumab + ipilimumab + SBRT).

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Phase 2, Randomized, Multi-institutional Study of Nivolumab and Ipilimumab Versus Nivolumab, Ipilimumab and Stereotactic Body Radiation Therapy for Metastatic Merkel Cell Carcinoma

Actual Study Start Date :

Mar 14, 2017

Actual Primary Completion Date :

Apr 6, 2022

Anticipated Study Completion Date :

Jul 1, 2023

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: Arm A: Nivolumab + Ipilimumab Nivolumab every 2 weeks and Ipilimumab every 6 weeks until progression or unacceptable toxicity.	Drug: Nivolumab Nivolumab 240 mg/dose intravenously (IV) every 2 (q2) weeks. Other Names: OPDIVO Drug: Ipilimumab Ipilimumab 1 mg/kg/dose IV q6 weeks. Other Names: YERVOY
Active Comparator: Arm B: Nivolumab + Ipilimumab + SBRT Nivolumab every 2 weeks and Ipilimumab every 6 weeks until progression or unacceptable toxicity. Stereotactic Body Radiation Therapy (SBRT) to be given at the start of week 2.	Drug: Nivolumab Nivolumab 240 mg/dose intravenously (IV) every 2 (q2) weeks. Other Names: OPDIVO Drug: Ipilimumab Ipilimumab 1 mg/kg/dose IV q6 weeks. Other Names: YERVOY Radiation: Stereotactic Body Radiation Therapy (SBRT) Stereotactic Body Radiation Therapy 24Gy in 3 fractions. Other Names: SBRT

Arm

Intervention/Treatment

Active Comparator: Arm A: Nivolumab + Ipilimumab

Nivolumab every 2 weeks and Ipilimumab every 6 weeks until progression or unacceptable toxicity.

Drug: Nivolumab

Nivolumab 240 mg/dose intravenously (IV) every 2 (q2) weeks.

Other Names:

OPDIVO

Drug: Ipilimumab

Ipilimumab 1 mg/kg/dose IV q6 weeks.

Other Names:

YERVOY

Active Comparator: Arm B: Nivolumab + Ipilimumab + SBRT

Nivolumab every 2 weeks and Ipilimumab every 6 weeks until progression or unacceptable toxicity. Stereotactic Body Radiation Therapy (SBRT) to be given at the start of week 2.

Drug: Nivolumab

Nivolumab 240 mg/dose intravenously (IV) every 2 (q2) weeks.

Other Names:

OPDIVO

Drug: Ipilimumab

Ipilimumab 1 mg/kg/dose IV q6 weeks.

Other Names:

YERVOY

Radiation: Stereotactic Body Radiation Therapy (SBRT)

Stereotactic Body Radiation Therapy 24Gy in 3 fractions.

Other Names:

SBRT

Outcome Measures

Primary Outcome Measures

Objective Response Rate [at 3 months]
Objective-response rate (ORR) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1: including Complete Response (CR) rate, Partial Response (PR) rate, and Stable Disease (SD) rate will be calculated through exact binomial distribution with a 2-sided 95% confidence interval among patients who obtain a least one dose of study drug.

Secondary Outcome Measures

Progression Free Survival (PFS) [36 months]
Median Progression Free Survival with 95% Confidence Interval. Progression is defined as progressive tumor lesions per immune-related Response Evaluation in Solid Tumors (irRECIST) definition, or appearance of one or more new Merkel cell carcinoma lesions, which can be local or distant in location from the irradiated lesions.
Overall Survival (OS) [24 months]
Median Overall Survival with 95% Confidence Interval. The length of time from the start of treatment until death from any cause.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

At least 18 years of age
Eastern Cooperative Oncology Group (ECOG) Performance Status less than 2
Active disease measurable by CT, MRI or clinical exam.
Prior chemotherapy or immunotherapy will be allowed if new or persistent measurable site(s) of disease are present.
Prior radiation therapy will be allowed if there is active measurable disease burden.
Must be either recurrent, unresectable or Stage IV American Joint Committee on Cancer (AJCC) (7th edition) and have histologically confirmed Merkel cell carcinoma with at least 2 distinct lesions in order to be eligible.
Must have at least 2 distinct lesions as documented by a complete physical examination or imaging studies within 4 weeks prior to randomization. Imaging studies must include a diagnostic CT scan of the involved disease sites and all known sites of resected disease and brain magnetic resonance (MRI) or CT (brain CT allowable if MRI is contraindicated or if there is no known history of resected brain lesions).
Tumor tissue from the core biopsy or resected site of disease must be provided for biomarker analyses.

Exclusion Criteria:

History of Grade 3 toxicity or use of infliximab with prior immunotherapy
Patients with active brain metastasis.
Active, known, or suspected autoimmune disease. Potential participants with type I diabetes mellitus, residual hypothyroidism due to autoimmune thyroiditis only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment are permitted to enroll.
Patients with prior history of non-Merkel cell carcinoma malignancies are excluded except adequately treated basal cell, squamous cell skin cancer, chronic lymphocytic leukemia or other indolent diseases not requiring therapy; adequately treated, with curative intent, cancer from which the patient is currently in complete remission per investigator's judgment; or patients with history of breast cancer and no evidence of disease on hormonal therapy to prevent recurrence and patients with prostate cancer on adjuvant hormonal therapy with undetectable PSA are eligible.
A condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of randomization. Inhaled or topical steroids are permitted in the absence of active autoimmune disease.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	H. Lee Moffitt Cancer Center and Research Institute	Tampa	Florida	United States	33612
2	Ohio State University Comprehensive Cancer Center	Columbus	Ohio	United States	43210